Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danazol for Telomere Related Diseases
NCT01441037Phase 2Completed
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Jul 2011
- Primary completion
- Nov 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of danazol in aplastic anemia and idiopathic pulmonary fibrosis (IPF), sponsored by National Heart, Lung, and Blood Institute. Primary endpoint: Number of Patients Having Attenuation of Accelerated Telomere Attrition at 24 months. Started Jul 2011; status: completed.
02
Drugs
danazol
03
Conditions
aplastic anemiaidiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT01441037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01441037.